These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18783801)

  • 1. Cerebrospinal fluid evidence of increased extra-mitochondrial glucose metabolism implicates mitochondrial dysfunction in multiple sclerosis disease progression.
    Regenold WT; Phatak P; Makley MJ; Stone RD; Kling MA
    J Neurol Sci; 2008 Dec; 275(1-2):106-12. PubMed ID: 18783801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cerebrospinal fluid lactate is associated with multiple sclerosis disease progression.
    Albanese M; Zagaglia S; Landi D; Boffa L; Nicoletti CG; Marciani MG; Mandolesi G; Marfia GA; Buttari F; Mori F; Centonze D
    J Neuroinflammation; 2016 Feb; 13():36. PubMed ID: 26863878
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort.
    Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E
    Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated cerebrospinal fluid lactate concentrations in patients with bipolar disorder and schizophrenia: implications for the mitochondrial dysfunction hypothesis.
    Regenold WT; Phatak P; Marano CM; Sassan A; Conley RR; Kling MA
    Biol Psychiatry; 2009 Mar; 65(6):489-94. PubMed ID: 19103439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients.
    Regenold WT; Hisley KC; Phatak P; Marano CM; Obuchowski A; Lefkowitz DM; Sassan A; Ohri S; Phillips TL; Dosanjh N; Conley RR; Gullapalli R
    Bipolar Disord; 2008 Nov; 10(7):753-64. PubMed ID: 19032707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.
    Leurs CE; Podlesniy P; Trullas R; Balk L; Steenwijk MD; Malekzadeh A; Piehl F; Uitdehaag BM; Killestein J; van Horssen J; Teunissen CE
    Mult Scler; 2018 Apr; 24(4):472-480. PubMed ID: 28294696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A metabolic perspective on CSF-mediated neurodegeneration in multiple sclerosis.
    Wentling M; Lopez-Gomez C; Park HJ; Amatruda M; Ntranos A; Aramini J; Petracca M; Rusielewicz T; Chen E; Tolstikov V; Kiebish M; Fossati V; Inglese M; Quinzii CM; Katz Sand I; Casaccia P
    Brain; 2019 Sep; 142(9):2756-2774. PubMed ID: 31305892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated cerebrospinal fluid glucose levels and diabetes mellitus are associated with activation of the neurotoxic polyol pathway.
    Tigchelaar C; van Zuylen ML; Hulst AH; Preckel B; van Beek AP; Kema IP; Hermanides J; Absalom AR
    Diabetologia; 2022 Jul; 65(7):1098-1107. PubMed ID: 35380232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transferrin in patients with multiple sclerosis: a comparison among various subgroups of multiple sclerosis patients.
    Zeman D; Adam P; Kalistová H; Sobek O; Kelbich P; Andel J; Andel M
    Acta Neurol Scand; 2000 Feb; 101(2):89-94. PubMed ID: 10685854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CSF nitric oxide metabolites are associated with activity and progression of multiple sclerosis.
    Rejdak K; Eikelenboom MJ; Petzold A; Thompson EJ; Stelmasiak Z; Lazeron RH; Barkhof F; Polman CH; Uitdehaag BM; Giovannoni G
    Neurology; 2004 Oct; 63(8):1439-45. PubMed ID: 15505162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid B cells and disease progression in multiple sclerosis - A longitudinal prospective study.
    Wurth S; Kuenz B; Bsteh G; Ehling R; Di Pauli F; Hegen H; Auer M; Gredler V; Deisenhammer F; Reindl M; Berger T
    PLoS One; 2017; 12(8):e0182462. PubMed ID: 28777826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum Compounds of Energy Metabolism Impairment Are Related to Disability, Disease Course and Neuroimaging in Multiple Sclerosis.
    Lazzarino G; Amorini AM; Petzold A; Gasperini C; Ruggieri S; Quartuccio ME; Lazzarino G; Di Stasio E; Tavazzi B
    Mol Neurobiol; 2017 Nov; 54(9):7520-7533. PubMed ID: 27826747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship of CSF neurotransmitter metabolite levels to disease severity and disability in multiple sclerosis.
    Markianos M; Koutsis G; Evangelopoulos ME; Mandellos D; Karahalios G; Sfagos C
    J Neurochem; 2009 Jan; 108(1):158-64. PubMed ID: 19014375
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sirtuins and Metabolism Biomarkers in Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: a Correlation Study with Clinical Outcomes and Cognitive Impairments.
    Foolad F; Samadi-Bahrami Z; Khodagholi F; Nabavi SM; Moore GRW; Javan M
    Mol Neurobiol; 2024 Jun; 61(6):3442-3460. PubMed ID: 37995076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mitochondrial dysfunction and serum lactate as a biomarker for the progression and disability in MS and its correlation with the radiological findings.
    Esmael A; Talaat M; Egila H; Eltoukhy K
    Neurol Res; 2021 Jul; 43(7):582-590. PubMed ID: 33657991
    [No Abstract]   [Full Text] [Related]  

  • 17. Composite cerebrospinal fluid score in relapsing-remitting and secondary progressive multiple sclerosis.
    Jongen PJ; Floris S; Doesburg WH; Lemmens WA; Hommes OR; Lamers KJ
    Mult Scler; 1998 Jun; 4(3):108-10. PubMed ID: 9762656
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum lactate as a novel potential biomarker in multiple sclerosis.
    Amorini AM; Nociti V; Petzold A; Gasperini C; Quartuccio E; Lazzarino G; Di Pietro V; Belli A; Signoretti S; Vagnozzi R; Lazzarino G; Tavazzi B
    Biochim Biophys Acta; 2014 Jul; 1842(7):1137-43. PubMed ID: 24726946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adiponectin in Cerebrospinal Fluid from Patients Affected by Multiple Sclerosis Is Correlated with the Progression and Severity of Disease.
    Signoriello E; Mallardo M; Nigro E; Polito R; Casertano S; Di Pietro A; Coletta M; Monaco ML; Rossi F; Lus G; Daniele A
    Mol Neurobiol; 2021 Jun; 58(6):2663-2670. PubMed ID: 33486671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abnormalities in the cerebrospinal fluid levels of endocannabinoids in multiple sclerosis.
    Di Filippo M; Pini LA; Pelliccioli GP; Calabresi P; Sarchielli P
    J Neurol Neurosurg Psychiatry; 2008 Nov; 79(11):1224-9. PubMed ID: 18535023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.